Gordon Wishart

From Wikipedia, the free encyclopedia

Professor Gordon C Wishart
Born (1960-09-03) 3 September 1960 (age 63)
Edinburgh, Scotland
NationalityScottish
Alma materUniversity of Edinburgh
Known forDiagnosis and treatment of breast cancer, development of Predict cancer survival model, founder of Check4Cancer Ltd
Scientific career
FieldsMedicine, oncology, surgical oncology
InstitutionsRoyal College of Surgeons of Glasgow, Royal College of Surgeons of England, Addenbrooke’s Hospital, Cambridge, University of Cambridge, Anglia Ruskin School of Medicine

Professor Gordon C. Wishart FRCS (Eng.) FRCS (Gen.) (3 September 1960-) is the founder, Chief Medical Officer, and CEO of Check4Cancer, an early cancer detection and prevention company. In 2016, Check4Cancer launched rapid access, streamlined, and audited diagnostic pathways for breast and skin cancer for the insured and self-pay markets, leading to the award of “Diagnostic Provider of the Year” at the annual Health Investor Awards in 2018. In late 2017, Check4Cancer launched the first worldwide breast cancer risk test (MyBreastRisk) to combine genetic, family history, and lifestyle risk factors to underpin a risk-stratified breast screening programme.

As the former Director of the Cambridge Breast Unit from 2005-2010, and current Professor of Cancer Surgery at Anglia Ruskin School of Medicine since 2008, he has contributed to clinical research and modernisation of cancer diagnosis and treatment, with more than 100 peer-reviewed papers in scientific journals. In 2010, he led a team of clinicians and scientists that developed the PREDICT breast cancer treatment and survival model, which is now used worldwide.

Early life and education[edit]

Gordon Cranston Wishart was born in Edinburgh, Scotland, on 3 September 1960.

He studied at the University of Edinburgh Medical School, where he received his MB ChB in July 1983. He subsequently obtained his MD from the University of Edinburgh in June 1992 with a thesis entitled Aspects of multidrug resistance in breast cancer.[1]

Research and publications[edit]

Wishart is notable for his prolific clinical research output, alongside his work as a practising breast and endocrine surgeon.

He has received the following prizes as recognition for his scientific contribution:

As of October 2009, he is principal investigator on the following studies:

  • Reasons for improved survival in screen-detected breast cancer
  • Development of a UK version of Adjuvantonline.
  • Infrared Imaging for breast cancer diagnosis
  • BT blood test for breast cancer detection

In addition, he is a co-investigator, surgical coordinator, or clinical surgical coordinator on an additional 15 research studies.[5]

His research has been published in The Lancet,[6] the British Journal of Cancer,[7][8][9][10][11] the British Medical Journal,[12] the Journal of Clinical Oncology,[13] and the British Journal of Surgery.[14][15]

Major achievements[edit]

  • In 1990, Wishart identified that P-glycoprotein, a trans-membrane export pump involved in multidrug resistance, was present in breast cancer.[16]
  • In 1998, Wishart introduced early patient discharge, with wound drains still in situ, following breast cancer surgery. Although controversial at the time, this technique has since been widely adopted.[17]
  • Wishart pioneered minimally invasive parathyroid surgery as a daycase procedure in the UK, together with the use of intraoperative parathyroid hormone (PTH) measurement for parathyroid surgery.[18]
  • In 2007, Wishart piloted gold seed insertion following breast conserving surgery for breast cancer to facilitate targeted radiotherapy.[19]
  • In 2009, Wishart pioneered preoperative axillary lymph node staging in breast cancer treatment.[20][21]

Current posts[edit]

Gordon Wishart currently holds the following posts:

He also acts as a referee for the British Journal of Surgery, the European Journal of Surgical Oncology, and Nuclear Medicine Communications.[citation needed]

References[edit]

  1. ^ Wishart, Gordon (1992). "Aspects of multidrug resistance in breast cancer". hdl:1842/20307. {{cite journal}}: Cite journal requires |journal= (help)
  2. ^ "Select My Surgeon - Gordon Wishart Profile". Archived from the original on 16 July 2011. Retrieved 28 October 2009.
  3. ^ Wiley Interscience
  4. ^ http://www.baes.info/Pages/newsletter_November_2007.pdf British Association of Endocrine and Thyroid Surgeons, Newsletter, November 2007
  5. ^ Gordon Wishart’s CV on Select My Surgeon[permanent dead link]
  6. ^ The importance, availability and measurement of oestrogen receptor (ER) status in the management of breast cancer in the United Kingdom – results of a nationwide survey. BJ Mander, K Heal, AD Purushotham, GC Wishart. The Lancet 1998; 352: 36-37
  7. ^ GC Wishart, JA Plumb, JJ Going, AM McNicol, CS McArdle, T Tsuruo, SB Kaye. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761
  8. ^ T Barrett, D J Bowden, D C Greenberg, C H Brown, G C Wishart, P D Britton. Radiological staging in breast cancer: which asymptomatic patients to image and how. British Journal of Cancer, 29 September 2009
  9. ^ S J Dawson, S W Duffy, F M Blows, K E Driver, E Provenzano, J LeQuesne, D C Greenberg, P Pharoah, C Caldas, G C Wishart. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009; 101: 1338-1344
  10. ^ L Hughes-Davies, C Caldas, G C Wishart. Tamoxifen: the drug that came in from the cold. British Journal of Cancer 2009; 101: 875-878
  11. ^ G C Wishart, D C Greenberg, P D Britton, P Chou, C H Brown, A D Purushotham, S W Duffy. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? British Journal of Cancer 2008; 98: 1741-1744
  12. ^ BJ Mander, GH Cunnick, M Daultrey, GC Wishart. Medical and psychological effects of early discharge after surgery for breast cancer. BMJ 1998; 317: 1081-1082
  13. ^ GC Wishart, D Bissett, J Paul, D Jodrell, A Harnett, T Habeshaw, DJ Kerr, MA Macham, M Soukop, RC Leonard. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial J Clin Oncol, 1 September 1994: 1771-1777
  14. ^ Gurnell E.M., Thomas S.K., McFarlane I., Munday I., Balan K.K., Berman L., Chatterjee V.K.K., Wishart G.C. Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure. British Journal of Surgery 2004, 91(1), pp. 78-82
  15. ^ Gupta, Y, Ahmed, R, Happerfield, L, Pinder, SE, Balan, KK, Wishart, GC. P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. British Journal of Surgery, 2007. 94(12) pp. 1491-1495
  16. ^ GC Wishart, JA Plumb, JJ Going, AM McNicol, CS McArdle, T Tsuruo, SB Kaye. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761
  17. ^ BJ Mander, GH Cunnick, M Daultrey, GC Wishart. Medical and psychological effects of early discharge after surgery for breast cancer. BMJ 1998; 317: 1081-1082
  18. ^ Gurnell EM, Thomas SK, McFarlane I, Munday I, Balan KK, Berman L, Chatterjee VKK, Wishart GC. Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure. British Journal of Surgery 2004, 91(1), pp. 78-82
  19. ^ Gold Seed Study: Evaluation of Tumour Bed Localisation and Image-guided Radiotherapy for Breast Cancer. On Behalf Of The Import Working Party, Coles CE, Wishart G, Donovan E, Harris E, Poynter A, Twyman N, Routsis D, Wilkinson J, Yarnold J. Clin Oncol (R Coll Radiol). 2007 Apr;19(3):S26-7.
  20. ^ Britton PD, Goud A, Godward S, Barter S, Freeman A, Gaskarth M, Rajan P, Sinnatamby R, Slattery J, Provenzano E, O’Donovan M, Pinder S , Benson J, Forouhi P, Wishart GC. Use of ultrasound-guided axillary node core biopsy in staging of early breast cancer. European Radiology 2009; 19: 561-569
  21. ^ Britton P D, Provenzano E, Barter S, Gaskarth M, Goud A, Moyle P, Sinnatamby R, Wallis M, Benson J R, Forouhi P, Wishart GC. Ultrasound-guided percutaneous axillary lymph node core biopsy: how often is the sentinel lymph node being biopsied? The Breast 2009; 18(1): 13-16.
  22. ^ Breast Cancer Risk for Daughters
  23. ^ Anglia Ruskin University – Pink Rose Appeal
  24. ^ University of Cambridge – Graces to be submitted to the Regent House at a Congregation on 22 July 2006

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Gordon_Wishart&oldid=1178653262"